-
公开(公告)号：US20130150450A1
公开(公告)日：2013-06-13
申请号：US13620761
申请日：2012-09-15
Applicant: Edward Holson , Florence F. Wagner , G. Patrick Stahly
Inventor： Edward Holson , Florence F. Wagner , G. Patrick Stahly
IPC: C07C233/80
CPC classification number: C07C233/80 , A61K31/167 , C07B2200/13 , C07C231/12 , C07C237/42
Abstract: Novel solid forms of tacedinaline (4-(acetylamino)-N-(2-aminophenyl)benzamide), including crystalline tacedinaline Forms A, B, and D, a novel crystalline tacedinaline TFA salt, and amorphous tacedinaline, are disclosed. Pharmaceutical compositions comprising crystalline tacedinaline Forms A, B, and D, the novel crystalline tacedinaline TFA salt, and/or amorphous tacedinaline, and methods of treating various conditions by administering those novel solid forms, are also disclosed.
-
2.发明授权Synthesis and regioselective substitution of 6-halo-and 6-alkoxy nicotine derivatives 失效6-卤代和6-烷氧基烟碱衍生物的合成和区域选择性取代公开(公告)号：US07820826B2
公开(公告)日：2010-10-26
申请号：US11693276
申请日：2007-03-29
Applicant: Daniel L. Comins , Florence F. Wagner , Pauline Ondachi
Inventor： Daniel L. Comins , Florence F. Wagner , Pauline Ondachi
IPC: C07D401/00 , A61K31/44
CPC classification number: C07D401/04 , C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D491/04
Abstract: The present invention provides active compounds for modulating nicotinic acetylcholine receptors and methods of making the same. The methods of preparing the active compounds utilize different intermediate compounds.
Abstract translation: 本发明提供用于调节烟碱乙酰胆碱受体的活性化合物及其制备方法。 制备活性化合物的方法使用不同的中间体化合物。
-
公开(公告)号：US20080261978A1
公开(公告)日：2008-10-23
申请号：US12073648
申请日：2008-03-07
Applicant: Michael P. Clark , Mark A. Lockwood , Florence F. Wagner , Michael G. Natchus
Inventor： Michael P. Clark , Mark A. Lockwood , Florence F. Wagner , Michael G. Natchus
IPC: A61K31/5377 , C07D211/70 , A61K31/44 , A61K31/17 , C07D265/30 , A61K31/5375 , A61K31/135 , C07D235/04 , A61K31/495 , C07D403/02 , A61P35/02 , A61P35/00 , A61K31/18 , C07C311/01 , A61K31/496 , C07D241/02 , C07D241/04 , A61K31/4184 , C07C211/00 , C07D413/02 , C07C275/00 , C07D239/02 , A61K31/505
CPC classification number: C07C275/40 , C07C237/30 , C07C237/32 , C07C237/34 , C07C275/24
Abstract: The invention provides compounds of Formula (I) and pharmaceutical compositions comprising compounds of Formula (I). These compounds are useful treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers
Abstract translation: 本发明提供式（I）化合物和包含式（I）化合物的药物组合物。 这些化合物可用于治疗或预防HIV感染，以及治疗增殖性疾病如抑制各种癌症的转移
-
公开(公告)号：US08729130B2
公开(公告)日：2014-05-20
申请号：US13620761
申请日：2012-09-15
Applicant: Edward Holson , Florence F. Wagner , G. Patrick Stahly
Inventor： Edward Holson , Florence F. Wagner , G. Patrick Stahly
IPC: A61K31/167 , C07C237/40 , A61P25/28 , A61P25/00 , A61P25/18 , A61P25/22 , A61P25/30
CPC classification number: C07C233/80 , A61K31/167 , C07B2200/13 , C07C231/12 , C07C237/42
Abstract: Novel solid forms of tacedinaline (4-(acetylamino)-N-(2-aminophenyl)benzamide), including crystalline tacedinaline Forms A, B, and D, a novel crystalline tacedinaline TFA salt, and amorphous tacedinaline, are disclosed. Pharmaceutical compositions comprising crystalline tacedinaline Forms A, B, and D, the novel crystalline tacedinaline TFA salt, and/or amorphous tacedinaline, and methods of treating various conditions by administering those novel solid forms, are also disclosed.
Abstract translation: 披露了一种新型固体形式的tacedinaline（4-（乙酰氨基）-N-（2-氨基苯基）苯甲酰胺），包括结晶的tacedinaline形式A，B和D，一种新型结晶的tacedineine TFA盐和无定形tacedinaline。 还公开了包含结晶哌啶酮A，B和D的药物组合物，新型结晶哌啶盐酸盐TFA盐和/或无定形泼尼汀，以及通过施用这些新型固体形式治疗各种病症的方法。
-
5.发明授权Synthesis and regioselective substitution of 6-halo- and 6-alkoxy nicotine derivatives 失效6-卤代和6-烷氧基尼古丁衍生物的合成和区域选择性取代公开(公告)号：US08389732B2
公开(公告)日：2013-03-05
申请号：US12879109
申请日：2010-09-10
Applicant: Daniel L. Comins , Florence F. Wagner , Pauline Ondachi
Inventor： Daniel L. Comins , Florence F. Wagner , Pauline Ondachi
IPC: C07D401/00 , A61K31/44
CPC classification number: C07D401/04 , C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D491/04
Abstract: The present invention provides active compounds for modulating nicotinic acetylcholine receptors and methods of making the same. The methods of preparing the active compounds utilize different intermediate compounds.
Abstract translation: 本发明提供用于调节烟碱乙酰胆碱受体的活性化合物及其制备方法。 制备活性化合物的方法使用不同的中间体化合物。
-
Patent Agency Ranking
公开(公告)号：US08338448B2
公开(公告)日：2012-12-25
申请号：US12414352
申请日：2009-03-30
Applicant: Michael P. Clark , Florence F. Wagner , Brandon C. Doroh , Tricia L. Johnson , Yesim Altas Tahirovic , Lawrence Wilson , John M. Wiseman , Jason W. Skudlarek , Mark A. Lockwood , Michael G. Natchus
Inventor： Michael P. Clark , Florence F. Wagner , Brandon C. Doroh , Tricia L. Johnson , Yesim Altas Tahirovic , Lawrence Wilson , John M. Wiseman , Jason W. Skudlarek , Mark A. Lockwood , Michael G. Natchus
IPC: A61K31/44 , C07D491/00
CPC classification number: A61K31/541 , A61K31/437 , A61K31/4709 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K45/06 , C07D401/12 , C07D403/14 , C07D471/04 , C07D487/04
Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts, solvates, tautomers, stereoisomers, and/or esters thereof. These compounds, and pharmaceutical composition comprising such compounds are useful treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers.
Abstract translation: 本发明提供式（I）化合物及其药学上可接受的盐，溶剂合物，互变异构体，立体异构体和/或其酯。 这些化合物和包含这些化合物的药物组合物可用于治疗或预防HIV感染，以及治疗增殖性疾病如抑制各种癌症的转移。
-
公开(公告)号：US20100029634A1
公开(公告)日：2010-02-04
申请号：US12414352
申请日：2009-03-30
Applicant: Michael P. Clark , Florence F. Wagner , Brandon C. Doroh , Tricia L. Johnson , Yesim Altas Tahirovic , Lawrence Wilson , John M. Wiseman , Jason W. Skudlarek , Mark A. Lockwood , Michael G. Natchus
Inventor： Michael P. Clark , Florence F. Wagner , Brandon C. Doroh , Tricia L. Johnson , Yesim Altas Tahirovic , Lawrence Wilson , John M. Wiseman , Jason W. Skudlarek , Mark A. Lockwood , Michael G. Natchus
IPC: A61K31/5377 , C07D471/04 , A61K31/437 , C07D401/12 , A61K31/4709 , C07D401/14 , A61K31/506 , A61K31/497 , A61P31/12 , A61P35/04
CPC classification number: A61K31/541 , A61K31/437 , A61K31/4709 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K45/06 , C07D401/12 , C07D403/14 , C07D471/04 , C07D487/04
Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts, solvates, tautomers, stereoisomers, and/or esters thereof. These compounds, and pharmaceutical composition comprising such compounds are useful treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers
Abstract translation: 本发明提供式（I）化合物及其药学上可接受的盐，溶剂合物，互变异构体，立体异构体和/或其酯。 这些化合物和包含这些化合物的药物组合物可用于治疗或预防HIV感染，以及治疗增殖性疾病如抑制各种癌症的转移
-
8.发明申请SYNTHESIS AND REGIOSELECTIVE SUBSTITUTION OF 6-HALO-AND 6-ALKOXY NICOTINE DERIVATIVES 失效6-HALO和6-ALKOXY NICOTINE衍生物的合成和选择性取代公开(公告)号：US20070232665A1
公开(公告)日：2007-10-04
申请号：US11693276
申请日：2007-03-29
Applicant: Daniel L. Comins , Florence F. Wagner , Pauline Ondachi
Inventor： Daniel L. Comins , Florence F. Wagner , Pauline Ondachi
IPC: A61K31/4439 , A61K31/4545 , C07F7/02 , C07F7/22 , C07D403/04 , C07D401/04
CPC classification number: C07D401/04 , C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D491/04
Abstract: The present invention provides active compounds for modulating nicotinic acetylcholine receptors and methods of making the same. The methods of preparing the active compounds utilize different intermediate compounds.
Abstract translation: 本发明提供用于调节烟碱乙酰胆碱受体的活性化合物及其制备方法。 制备活性化合物的方法使用不同的中间体化合物。
-
公开(公告)号：US20130102677A1
公开(公告)日：2013-04-25
申请号：US13620772
申请日：2012-09-15
Applicant: Edward Holson , Florence F. Wagner , G. Patrick Stahly
Inventor： Edward Holson , Florence F. Wagner , G. Patrick Stahly
IPC: A61K31/167
CPC classification number: C07C233/80 , A61K31/167 , C07B2200/13 , C07C231/12 , C07C237/42
Abstract: Novel solid forms of tacedinaline (4-(acetylamino)-N-(2-aminophenyl)benzamide), including crystalline tacedinaline Forms A, B, and D, a novel crystalline tacedinaline TFA salt, and amorphous tacedinaline, are disclosed. Pharmaceutical compositions comprising crystalline tacedinaline Forms A, B, and D, the novel crystalline tacedinaline TFA salt, and/or amorphous tacedinaline, and methods of treating various conditions by administering those novel solid forms, are also disclosed.
Abstract translation: 披露了一种新型固体形式的tacedinaline（4-（乙酰氨基）-N-（2-氨基苯基）苯甲酰胺），包括结晶的tacedinaline形式A，B和D，一种新型结晶的tacedineine TFA盐和无定形tacedinaline。 还公开了包含结晶哌啶酮A，B和D的药物组合物，新型结晶哌啶盐酸盐TFA盐和/或无定形泼尼汀，以及通过施用这些新型固体形式治疗各种病症的方法。
-
公开(公告)号：US08691875B2
公开(公告)日：2014-04-08
申请号：US13620772
申请日：2012-09-15
Applicant: Edward Holson , Florence F. Wagner , G. Patrick Stahly
Inventor： Edward Holson , Florence F. Wagner , G. Patrick Stahly
IPC: A61K31/167 , C07C237/40 , A61P25/28 , A61P25/00 , A61P25/18 , A61P25/22 , A61P25/30
CPC classification number: C07C233/80 , A61K31/167 , C07B2200/13 , C07C231/12 , C07C237/42
Abstract: Novel solid forms of tacedinaline (4-(acetylamino)-N-(2-aminophenyl)benzamide), including crystalline tacedinaline Forms A, B, and D, a novel crystalline tacedinaline TFA salt, and amorphous tacedinaline, are disclosed. Pharmaceutical compositions comprising crystalline tacedinaline Forms A, B, and D, the novel crystalline tacedinaline TFA salt, and/or amorphous tacedinaline, and methods of treating various conditions by administering those novel solid forms, are also disclosed.
Abstract translation: 披露了一种新型固体形式的tacedinaline（4-（乙酰氨基）-N-（2-氨基苯基）苯甲酰胺），包括结晶的tacedinaline形式A，B和D，一种新型结晶的tacedineine TFA盐和无定形tacedinaline。 还公开了包含结晶哌啶酮A，B和D的药物组合物，新型结晶哌啶盐酸盐TFA盐和/或无定形泼尼汀，以及通过施用这些新型固体形式治疗各种病症的方法。
-
-
-
-
-
-
-
-
-
Search Results
12
records
(took 0.023 seconds)
